SILVIA ORTEGA GUTIÉRREZ-rekin lankidetzan egindako argitalpenak (4)

2022

  1. Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice

    Journal of Medicinal Chemistry, Vol. 65, Núm. 16, pp. 10956-10974

2021

  1. Chemistry for the Identification of Therapeutic Targets: Recent Advances and Future Directions

    European Journal of Organic Chemistry, Vol. 2021, Núm. 9, pp. 1307-1320

  2. Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson-Gilford Progeria Syndrome

    ACS Central Science, Vol. 7, Núm. 8, pp. 1300-1310

2020

  1. A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

    Journal of Medicinal Chemistry, Vol. 63, Núm. 5, pp. 2372-2390